The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules
The programmed cell death ligand protein 1 (PD-L1) is a member of the B7 protein family and consists of 290 amino acid residues. The blockade of the PD-1/PD-L1 immune checkpoint pathway is effective in tumor treatment. Results: Two pharmacophore models were generated based on peptides and small mole...
Main Authors: | Yanwen Zhong, Xuanyi Li, Hequan Yao, Kejiang Lin |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-05-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/24/10/1940 |
Similar Items
-
Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
by: Mohammad Reza Javan, et al.
Published: (2016-08-01) -
Big peptide drugs in a small molecule world
by: Laszlo Otvos, et al.
Published: (2023-12-01) -
Editorial: Small molecules and peptides in paracrine/autocrine regulation of ovarian folliculogenesis
by: So-Youn Kim, et al.
Published: (2023-03-01) -
PD-1/PD-L1 inhibitor therapy: transitioning from a second-line to a first-line therapy for non-small cell lung cancer
by: Jong-Mu Sun
Published: (2017-03-01) -
Pharmacophore modeling for the identification of small-molecule inhibitors of TACE
by: Liu, Li-Juan, et al.
Published: (2016)